OHE 0.00% $1.10 orion health group limited

Ann: GENERAL: OHE: Groundbreaking health sector research programme

  1. lightbulb Created with Sketch. 2
    • Release Date: 10/03/16 12:28
    • Summary: GENERAL: OHE: Groundbreaking health sector research programme
    • Price Sensitive: No
    • Download Document  3.95KB
    					OHE
    10/03/2016 12:27
    GENERAL
    NOT PRICE SENSITIVE
    REL: 1227 HRS Orion Health Group Limited
    
    GENERAL: OHE: Groundbreaking health sector research programme
    
    10 March 2016
    
    Groundbreaking health sector research programme announced
    
    Orion Health joins with University of Auckland, Waitemata District Health
    Board, and Ministry of Business, Innovation and Employment on $37.8 million
    research programme to position NZ as global leader in Precision Medicine
    
    Auckland, 10 March - Orion Health (NZX:OHE) today announces a multi-million
    dollar health technology research venture aimed at improving the healthcare
    of all New Zealanders through the advancement of precision medicine.
    
    The Precision Driven Health research programme is a major public-private
    venture between industry, government and academia. The founding participants
    are Orion Health, Waitemata District Health Board and the University of
    Auckland, with support from the Ministry of Business Innovation and
    Employment. It is intended that a combined $37.8 million will be invested in
    the programme over seven years in the new area of precision medicine.
    
    Precision medicine is enabled when all information that is pertinent to a
    person's health and wellbeing - clinical, genetic, device (e.g. fitness
    apps), environmental and lifestyle factors - is combined and made available
    to the health professional and the patient. This allows them to make the best
    decisions regarding the patient's treatment plan.
    
    "Precision medicine is the future of health. New Zealand can lead the world
    in this area," says Ian McCrae, Orion Health CEO.
    
    "Existing medical data sources are not sufficient to enable personalised care
    because past health care is not the sole predictor of someone's future health
    - genetics, social circumstances, environmental exposure, and behavourial
    patterns all play a part," he says.
    
    "This research will offer the potential for improved patient health outcomes
    through care more precisely tailored to individual needs. This includes an
    improved suite of clinical decision support tools for doctors, the potential
    to more accurately predict disease risk factors and enabling patients to be
    in control of managing key risks to their health."
    
    Mr McCrae says he expects the results of the Precision Driven Health research
    venture to feed directly into Orion Health's product roadmap in time. It will
    contribute to existing products such as Orion Health's Amadeus platform,
    which includes the popular Rhapsody Integration Engine used by health
    providers globally.
    
    "It is exciting how much potential this research has to transform healthcare;
    greatly improving treatment, and in some cases saving lives," Mr McCrae says.
    
    It is intended that over time Orion Health and industry participants will
    make up $23.8 million of the funding, which includes a personal contribution
    by Mr McCrae. This would then be matched by $14 million of funding through
    the Ministry of Business, Innovation and Employment's research partnerships
    programme.
    
    Additional major commercial, healthcare provider and research participants
    are expected to join the venture in the coming months.
    
    -Ends-
    
    For Investor Relations enquiries
    Graeme Wilson
    
    Chief Operating Officer
    
    M: +64 21 101 3631
    [email protected]
    
    For media enquires
    
    Sarah Putt
    Corporate Marketing Manager
    M: +64 21 610 592
    E: [email protected]
    
    About Orion Health
    Orion Health (NZX:OHE) is a technology company that provides solutions which
    enable healthcare to over 90 million patients in more than 25 countries. Its
    open technology platform seamlessly integrates all forms of relevant data to
    enable population and personalised healthcare around the world. The company
    employs over 1250 people globally and is committed to continual innovation,
    investing over 30% of total operating revenue year to date in research and
    development, to cement its position at the forefront of precision medicine.
    For more information visit www.orionhealth.com
    End CA:00279086 For:OHE    Type:GENERAL    Time:2016-03-10 12:28:00
    				
 
watchlist Created with Sketch. Add OHE (NZSX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.